Concepedia

Ketil André Camilio

KA

Statistics

Publications

12

Citations

725

H-Index

12

Active since

2010

Affiliations

Lytix Biopharma (Norway)(Current)

UiT The Arctic University of Norway

Oslo University Hospital

University of Bergen

University of Oslo

Ketil André Camilio is an author at Lytix Biopharma (Norway) specializing in oncology, tumor immunology, and cancer immunotherapy.

ORCID

Publications per year

2010–2023

12

Publications

12

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Bengt Erik Haug, Ketil André Camilio, Liv Tone Eliassen et al. · Journal of Medicinal Chemistry · 2016 · 113 citations · Full text

, , +13

LTX-315: A First-In-Class Oncolytic Peptide that Reprograms the Tumor Microenvironment

Baldur Sveinbj⊘rnsson, Ketil André Camilio, Bengt Erik Haug et al. · Future Medicinal Chemistry · 2017 · 85 citations · Full text

, , +17

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

Ketil André Camilio, Gerd Marit Berge, Chandra Sekhar Ravuri et al. · Cancer Immunology Immunotherapy · 2014 · 81 citations · Full text

, , +17

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean‐François Baurain et al. · Clinical Cancer Research · 2021 · 75 citations · Full text

, , +14

Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

Gerd Marit Berge, Liv Tone Eliassen, Ketil André Camilio et al. · Cancer Immunology Immunotherapy · 2010 · 69 citations · Full text

, , +17

1–5 of 12